CTNM · Contineum Therapeutics, Inc. · Metrics
$8.31
-0.09 (-1.01%)
At close · Oct 23
Return incl. dividend (before tax)
Market Cap
$312.63M
Shares
37.62M
Volume · Oct 23
428.77K
Avg daily vol (3M)
802.72K
CTNM metrics
60 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$8.31
Market cap
$312.63M
Price action
20 metricsPrice change (1W)
+17.4%
Price change (30D)
-33.8%
Price change (3M)
-40.9%
Price change (6M)
-33.0%
Price change (YTD)
-27.3%
Price change (1Y)
-25.3%
Trailing year
Price change (5Y)
—
52-week high
$17.57
52-week low
$7.08
Change from 52-week high
-52.7%
Change from 52-week low
+17.4%
Annualized volatility
78.5%
Annualized volatility (3M)
102.6%
Beta
1.4
RSI (14D)
32.7
Price vs SMA 50
-37.6%
Price vs SMA 200
-38.8%
Avg volume (3M)
802,720
Relative volume
0.5
Average dollar volume
$9.60M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
37.62M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.3
reciprocal yield 76.7%
FCF yield
-17.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-18.4%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2025-10-30
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$66.38M
Net income (TTM)
−$57.56M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+44.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-24.0%
Return on assets
-23.0%
Debt / equity
0.0
Current ratio
37.2
EBITDA (TTM)
−$66.00M
Free cash flow (TTM)
−$53.46M
Quick ratio
37.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$236.55M
Latest balance sheet
Cash & equivalents
$14.71M
Total assets
$250.37M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$53.01M
Capital expenditures (TTM)
$458,000
R&D (TTM)
$48.10M
SG&A (TTM)
—
Stock compensation (TTM)
$12.71M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
102
13F filer change QoQ
+12
Institutional ownership
81.2%
Conviction holders (share of 13F filers)
3.9%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-10.4%
Holder tenure
5.9
Price vs estimated holder cost
+24.7%
Ownership (registered funds)
1 metricsIndex-fund ownership
8.3%
Short interest
3 metricsShort interest
8.2%
Latest settlement · 3.6 days to cover
Days to cover
3.6d
Short-squeeze score
55 / 100
Insider activity
2 metricsNet insider buying (90D)
−$81,170
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—